Numerous updates surround Agilent Technologies (A), with several investment analysts offering estimates and ratings. Agilent's performance, particularly its recent FDA expansion of Keytruda companion diagnostic, has raised questions about the company's valuation. The potential 34.86% upside in the company's share price has amplified investor interest. Agilent also announced a possible revision of investor sentiment following the new PD-L1 test approval and recent dividend news. HSBC and BofA have made significant announcements about the stock, maintaining a 'buy' and 'hold' rating, respectively. The company's CEO shared its payout for 2025, suggesting continued growth. Recent performance review, AI-driven price forecasts and comparison with the sector valuation have all been largely positive. Wall Street has shared insights on Agilent’s Q1 earnings and key metrics after a surge in revenue. The company has also launched a new AI Slide Scanner in Europe, which could potentially alter its diagnostic narrative, and showed robust revenue growth while raising its 2026 outlook. The company also announced a cash dividend of 25.5 cents per share. The company has kept its focus on growth through organic and inorganic means.
Agilent Technologies A News Analytics from Tue, 01 Jul 2025 07:00:00 GMT to Sat, 21 Feb 2026 02:09:15 GMT -
Rating 8
- Innovation 8
- Information 8
- Rumor 3
